Clinical Cancer Research, Vol 4, Issue 3 605-610, Copyright © 1998 by American Association for Cancer Research

ARTICLES

A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate

AC McDonald, PA Vasey, L Adams, J Walling, JR Woodworth, T Abrahams, S McCarthy, NP Bailey, N Siddiqui, MJ Lind, AH Calvert, CJ Twelves, J Cassidy and SB Kaye
CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom. alecm@ccotrust.co.uk

LY231514 is a novel antifolate that principally inhibits thymidylate synthase, but with additional folate-dependent enzyme targets. A Phase I study of single-agent LY231514 administered as a daily i.v. infusion over 10 minutes for 5 days, repeated every 3 weeks, was conducted to evaluate the maximum tolerated dose, pharmacokinetic profile, and antitumor activity of the drug using this schedule. Thirty-eight patients with advanced malignancies that were refractory or not amenable to standard therapy were treated with a total of 116 courses of LY231514, escalating treatment doses through 10 dose levels, from 0.2-5.2 mg/m2/day. No objective clinical responses were observed, although minor antitumor activity not fulfilling the response criteria was seen in three patients. A maximum tolerated dose of 4.0 mg/m2/day was determined, with neutropenia as the predominant dose-limiting toxicity. Reversible disturbances of liver biochemistry, fulfilling the protocol definitions of dose-limiting toxicity, were also observed. Other toxicities included diarrhea, mucositis, skin rash, and fatigue. Pharmacokinetic studies were performed at all treatment levels. Analysis showed a linear relation between administered dose and both maximum plasma concentration (Cmax) and area under the plasma concentration/time curve. The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h. When given by this schedule, LY231514 is tolerable, and Phase II studies are in progress.

This article has been cited by other articles:

				Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al. Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212. [Abstract] [Full Text] [PDF]

				A. H. Calvert and R. Plummer The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3664 - 3669. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 28 - 36. [Abstract] [Full Text] [PDF]

				S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]

				A. C. Mita, C. J. Sweeney, S. D. Baker, A. Goetz, L. A. Hammond, A. Patnaik, A. W. Tolcher, M. Villalona-Calero, A. Sandler, T. Chaudhuri, et al. Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function J. Clin. Oncol., February 1, 2006; 24(4): 552 - 562. [Abstract] [Full Text] [PDF]

				C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937. [Abstract] [Full Text] [PDF]

				S. Dubey and J. H. Schiller Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab Oncologist, April 1, 2005; 10(4): 282 - 291. [Abstract] [Full Text] [PDF]

				A.-R. Hanauske, V. Chen, P. Paoletti, and C. Niyikiza Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors Oncologist, August 1, 2001; 6(4): 363 - 373. [Abstract] [Full Text] [PDF]

				D. H. Patel, J. A. Allay, J. A. Belt, and B. P. Sorrentino Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells Blood, April 1, 2000; 95(7): 2356 - 2363. [Abstract] [Full Text] [PDF]

				B. A. Teicher, V. Chen, C. Shih, K. Menon, P. A. Forler, V. G. Phares, and T. Amsrud Treatment Regimens Including the Multitargeted Antifolate LY231514 in Human Tumor Xenografts Clin. Cancer Res., March 1, 2000; 6(3): 1016 - 1023. [Abstract] [Full Text]

				R. Thodtmann, H. Depenbrock, H. Dumez, J. Blatter, R. D. Johnson, A. van Oosterom, and A.-R. Hanauske Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin J. Clin. Oncol., October 1, 1999; 17(10): 3009 - 3016. [Abstract] [Full Text] [PDF]